David J. Warren

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Guro Løvik Goll et al. · The Lancet · 2017 · 806 citations

Pharmacy, Internal Medicine, Pharmacotherapy +11

Synergy of interleukin 1 and granulocyte colony-stimulating factor: in vivo stimulation of stem-cell recovery and hematopoietic regeneration following 5-fluorouracil treatment of mice.

M A Moore, David J. Warren · Proceedings of the National Academy of Sciences · 1987 · 369 citations · Full text

Life Sciences, Immunology, Oncology +17

Detection of eosinophils using an eosinophil peroxidase assay. Its use as an assay for eosinophil differentiation factors

Malcolm Strath, David J. Warren, Colin J. Sanderson · Journal of Immunological Methods · 1985 · 303 citations

Life Sciences, Immunology, Pathology +13

Identification of a lymphokine that stimulates eosinophil differentiation in vitro. Its relationship to interleukin 3, and functional properties of eosinophils produced in cultures.

Colin J. Sanderson, David J. Warren, Malcolm Strath · The Journal of Experimental Medicine · 1985 · 295 citations · Full text

Life Sciences, Immunology, Pathology +11

Eosinophil differentiation factor also has B-cell growth factor activity: proposed name interleukin 4.

Colin J. Sanderson, Anne O’Garra, David J. Warren et al. · Proceedings of the National Academy of Sciences · 1986 · 193 citations · Full text

Life Sciences, Hematology, Immunology +14